Share:
Peer-Reviewed Publication
Int J Mol Sci2026;27(4)February 18, 2026Journal Article

Novel Small-Molecule Analogues of IU1 Ameliorate Amyloid-β Mediated Toxicity in Alzheimer's Disease Cell and Worm Models.

Ajish Ariyath1,2, Fraulein Denise Arigo1,2, Izhar Wallach3, W M A D Binosha Fernando1,2, Ralph N Martins1,2,4, Prashant Bharadwaj1,2,5
1Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Sarich and Patricia Neuroscience Research Institute, Edith Cowan University, Joondalup, WA 6027, Australia.
2Alzheimer's Research Australia, Nedlands, WA 6009, Australia.
3Atomwise, 250 Sutter St, Suite 650, San Francisco, CA 94108, USA.
4School of Biomedical Science, Macquarie University, Sydney, NSW 2109, Australia.
5Curtin Medical School, Curtin Health and Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Perth, WA 6107, Australia.

Abstract

Dysregulation of the deubiquitinating enzyme Ubiquitin-specific peptidase 14 (USP14) is implicated in several neurodegenerative diseases, and IU1, an allosteric inhibitor, has shown neuroprotective effects by reducing protein aggregate toxicity. This study aimed to develop new IU1 analogues and evaluate their ability to mitigate amyloid-β (Aβ) accumulation and toxicity in Alzheimer's disease (AD)…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.